Please ensure Javascript is enabled for purposes of website accessibility

Why Amicus Therapeutics Shares Are Up Today

By Todd Campbell - Mar 1, 2016 at 3:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Late-stage data on its Fabry disease therapy is encouraging investors to think a future approval could be in the cards.

IMAGE SOURCE: AMICUS THERAPEUTICS.

What: After Amicus Therapeutics (FOLD 0.56%) reported new phase 3 data for its lead product candidate, its stock jumped higher by 10% at 3:00 p.m. ET today.

So what: The clinical-stage drugmaker is awaiting an EU decision on the approval of Galafold, a therapy for use in treating Fabry disease, a rare genetic condition.

Currently, Fabry disease is treated in the EU with Shire's (NASDAQ: SHPG) enzyme replacement therapy Replagel, a six-figure-per-year therapy that pulled in about $440 million in sales last year.

In phase 3 trials, patients who hadn't been treated with an ERT like Replagel saw a statistically significant improvement in podocytes, or cells in the kidney that help filter blood and that build up in Fabry disease patients.

Amicus Therapeutics also reported that Galafold's effects on kidney and cardiac function persisted in a subset of patients who switched over to its 19- to 30-month extension study.

Now what: Following its admission last year that its timeline for a Food and Drug Administration application and approval is uncertain, Amicus Therapeutics shares have tumbled. However, given Shire's success, an approval in the EU could still be significant. Furthermore, because Galafold works differently than Replagel, it could eventually be used alongside it as part of a standard of care, rather than instead of it, and that could boost its market opportunity.

Given that Amicus Therapeutics' market cap is just $770 million, that market opportunity is intriguing. However, the U.S. market is a big question mark and therefore, until an EU decision on Galafold and a timeline for its potential use in America is announced, buyers should approach this company cautiously. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amicus Therapeutics, Inc. Stock Quote
Amicus Therapeutics, Inc.
FOLD
$10.80 (0.56%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.